MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4726
-0.0174
-3.55%
After Hours: 0.4798 +0.0072 +1.52% 17:51 09/24 EDT
OPEN
0.4800
PREV CLOSE
0.4900
HIGH
0.5099
LOW
0.4600
VOLUME
756.71K
TURNOVER
--
52 WEEK HIGH
3.750
52 WEEK LOW
0.4224
MARKET CAP
22.67M
P/E (TTM)
-0.1013
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aravive Appoints Michael W. Rogers to Board of Directors
Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC)HOUSTON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that Michael
GlobeNewswire · 09/17 12:00
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
Acorda Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Benzinga · 08/05 10:07
Acorda Therapeutics EPS beats by $0.05, beats on revenue
Acorda Therapeutics (NASDAQ:ACOR): Q2 Non-GAAP EPS of -$0.35 beats by $0.05; GAAP EPS of -$0.37 beats by $0.17. Revenue of $33.62M (-32.8% Y/Y) beats by $6
seekingalpha · 08/05 01:07
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:15
Acorda Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Benzinga · 08/04 21:17
Acorda Therapeutics: Q2 Earnings Insights
Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 20% after the company reported Q2 results.Quarterly Results Earnings per share rose 36.36% year over year to ($0.35), which beat the estimate of ($0.48).Revenue of $33,617,000 decreased by 32.84% from
Benzinga · 08/04 20:20
Acorda Therapeutics Q2 EPS $(0.35) Beats $(0.48) Estimate, Sales $33.62M Beat $27.50M Estimate
Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.48) by 27.08 percent. This is a 36.36 percent increase over losses of $(0.55) per share
Benzinga · 08/04 20:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACOR. Analyze the recent business situations of Acorda through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACOR stock price target is 2.600 with a high estimate of 5.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 213
Institutional Holdings: 26.60M
% Owned: 55.46%
Shares Outstanding: 47.97M
TypeInstitutionsShares
Increased
14
1.44M
New
61
-3.16M
Decreased
28
17.04M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Non-Executive Chairman/Independent Director
John Kelley
Chief Executive Officer/President/Director
Ron Cohen
Chief Accounting Officer
David Lawrence
Other
Burkhard Blank
Other
Lauren Sabella
Independent Director
Barry Greene
Independent Director
Peder Jensen
Independent Director
Sandra Panem
Independent Director
Lorin Randall
Independent Director
Steven Rauscher
Independent Director
Catherine Strader
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.